Follow us on Twitter
twitter icon@FreshPatents


Mammal patents

      

This page is updated frequently with new Mammal-related patent applications.




 Protective agent for electron microscopic observation of biological sample in water-containing state, kit for electron microscopic observation, methods for observation, diagnosis, evaluation, and quantification by electron microscope, and sample stage patent thumbnailProtective agent for electron microscopic observation of biological sample in water-containing state, kit for electron microscopic observation, methods for observation, diagnosis, evaluation, and quantification by electron microscope, and sample stage
Provided are a protective agent for electron microscopic observation in a vacuum which can protect a biological sample in a water-containing state, such as a mammal, a plant tissue or a cultured cell, and a single cell in the living state without deforming it even in a vacuum, a kit using the same, methods for observation, diagnosis, evaluation, and quantification of a sample by an electron microscope, and a sample stage to be used for the observation. The protective agent for electron microscopic observation of the present invention contains a a component to impart the survival environment, a saccharide, and an electrolyte..
Japan Science And Technology Agency


 Reporter of genomic methylation and uses thereof patent thumbnailReporter of genomic methylation and uses thereof
In some aspects, described herein is a dna methylation reporter. In some aspects, the dna methylation reporter comprises a promoter whose activity can be affected by exogenous methylation changes without being independently regulated by the dna methylation machinery, operably linked to a dna sequence that encodes a reporter molecule.
Whitehead Institute For Biomedical Research


 Delivery of packaged rna to mammalian cells patent thumbnailDelivery of packaged rna to mammalian cells
Described herein are compositions relating to alphavirus-based virus-like particles (vlps) and methods for making and using the described vlps. The described compositions include vlps and vectors and cells used to produce the vlps.
The Usa , As Represented By The Secretary, Dept. Of Health And Human Services


 De-immunized shiga toxin a subunit effector polypeptides for applications in mammals patent thumbnailDe-immunized shiga toxin a subunit effector polypeptides for applications in mammals
The present invention relates to shiga toxin effector polypeptides with reduced antigenic and/or immunogenic potential. Immunogenicity can be a limitation for the repeated administration to mammals of proteins and polypeptides derived from shiga toxins.
Molecular Templates, Inc.


 Pharmaceutical composition containing a mixture of proenzymes and enzymes patent thumbnailPharmaceutical composition containing a mixture of proenzymes and enzymes
Pharmaceutical composition containing a mixture of proenzymes and enzymes, containing proenzymes trypsinogen and chymotrypsinogen and enzymes ct-amylase and lipase as active substances, and one or more pharmaceutically acceptable excipients, for simultaneous, separate and subsequent administration of the composition in parenteral or transmucosal way, the composition has anti-proliferative and anti-metastatic effects to cancer tumours and is intended for therapeutic, prophylactic and anti-metastatic use in mammals.. .

 Therapeutic methods patent thumbnailTherapeutic methods
The invention provides a method for a disease or condition associated with dopamine deficiency (e.g. Depression, schizophrenia, or parkinson's disease) in a mammal in need of such treatment comprising administering a compound that binds to rxr to the mammal..
Arizona Board Of Regents On Behalf Of Arizona State University


 Liquid non-ionic salt-free skin and hair treatment composition that contains lauroyl n-methyl glucamide patent thumbnailLiquid non-ionic salt-free skin and hair treatment composition that contains lauroyl n-methyl glucamide
Compositions and methods for their use in treating human or other mammalian skin and hair. Non-ionic, salt-free non-solidifying formulations of lauroyl n methyl glucamide and alkyl glycosides are disclosed that impart beneficial barrier properties to skin and hair..
Formula Xo, Inc.


 Atraumatic occlusion balloons and skirts, and methods of use thereof patent thumbnailAtraumatic occlusion balloons and skirts, and methods of use thereof
One aspect of the present invention relates to catheters that can be placed in or around bodily conduits to occlude or widen a biological lumen without imparting significant trauma to the lumen. In certain embodiments, the invention particularly relates to the use of a polymer composition which can be made to gel upon insertion into said balloon or skirt.
Genzyme Corporation


 Methods and kits for assessing heparanase procoagulant activity, compositions comprising heparanase, and methods for the treatment of coagulation related disorders patent thumbnailMethods and kits for assessing heparanase procoagulant activity, compositions comprising heparanase, and methods for the treatment of coagulation related disorders
Methods and kits for determining deparanase procoagulant activity in a biological sample. Diagnostic methods for the detection and/or monitoring of a coagulation-related pathological disorder in a mammalian subject.
Rambam Med-tech


 Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors patent thumbnailAnti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors
Polypeptides and proteins that specifically bind to and immunologically recognize ny-br-1 are disclosed. Chimeric antigen receptors (cars), anti-ny-br-1 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


Use of peptidylglycine alpha-amidating monooxigenase (pam) for c-terminal amidation

One aspect as reported herein is a method for in vivo c-terminal amidation of a polypeptide characterized in that both the polypeptide (to be amidated) and human peptidylglycine alpha-amidating monooxigenase (pam) are recombinantly co-expressed in a mammalian cell.. .
Hoffmann-la Roche Inc.

Capsid-modified, raav3 vector compositions and uses in gene therapy of human liver cancer

Disclosed are next-generation multi-mutated capsid protein-modified raav expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using these high transduction efficiency vector constructs in a variety of therapeutic applications including, inter alia, as delivery agents for the treatment or amelioration of one or more diseases or abnormal conditions in an affected mammal using in vivo and/or ex situ viral vector-based gene therapy protocols.
University Of Florida Research Foundation, Inc.

Dna element having the activity of enhancing foreign gene expression

Disclosed is a method for stably achieving high expression of a foreign gene in mammalian cells using a novel dna element. More specifically disclosed is a dna element which enhances the activation of transcription by changing the chromatin structure around a gene locus into which a foreign gene expression unit has been introduced..
Daiichi Sankyo Company, Limited

Saccharide-modified nucleic acid molecules

The present invention refers to the transfection of cells using a conjugate comprising at least one saccharide residue at least one nucleosidic component selected from nucleic acids, nucleosides and nucleotides. This conjugate is suitable for the transfection of prokaryotic and eukaryotic cells such as plant cells or mammalian cells including human cells with high efficacy.
Basf Se

Antibodies directed against interleukin-33 (il-33)

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (il-33). The invention provides an il-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide.
Anaptysbio,inc.

Implantable fluid management system for the removal of excess fluid

An implantable fluid management device, designed to drain excess fluid from a variety of locations in a living host into a second location within the host, such as the bladder of that host. The device may be used to treat ascites, chronic pericardial effusions, normopressure hydrocephalus, hydrocephalus, pulmonary edema, or any fluid collection within the body of a human, or a non-human mammal..
Sequana Medical Ag

Epicutaneous immunorebalancing

The present invention relates to compositions and methods for improving a subject condition by epicutaneous immunobalancing. The invention shows that particular regulatory t cells can be induced and maintained in a subject by epicutaneous treatment, thereby causing a substantial improvement in a subject condition.
Dbv Technologies

Composition comprising a uridine source, an omega-3 pufa for improving coordination, balance, grip strength or fine motor skills

Composition comprising a uridine source, an omega-3 pufa for improving coordination, balance, grip strength or fine motor skills. The invention is directed to a combination of a uridine source and an omega-3-polyunsaturated fatty acid having 18-24 carbon atoms for use in •—the prevention or treatment of a disturbance in coordination of limbs in a mammal •—the prevention or treatment of a disturbance in equilibrium in a mammal •—for use in the prevention or treatment of a disturbance in limb strength •—or use in the prevention or treatment of a disturbance in a motor skill in a mammal..
N. V. Nutricia

Orthogonatisches sage- und positionierungsimplantat

The invention concerns a bone joining implant (1) for joining of a first bone section (2) with a second bone section (3) of a mammal bone (4) with a first attachment area (6), displaying several holes for fastening elements (5a), prepared for attachment to the first bone section (2), and a second attachment area (7), linked to the first attachment area (6), with the second attachment area (7) also displaying several holes for fastening elements (5b), also prepared for attachment to the second bone section (3), with formation of a separating tool guidance contour (9) between the first and second attachment areas (6, 7), defining a cutting line (8), as well as a procedure for the individualized manufacture of such a bone joining implant (1).. .
Firma Karl Leibinger Medizintechnik Gmbh & Co. Kg

Sample collection devices and associated systems and methods

A sample collection apparatus or device, various abrasive devices or components, and methods for their use, are provided for collecting samples from within a mammalian body. Tissue collection and sample preparation is the gold standard in cytology.
Northwestern University

Honeybee repellents and uses thereof

The present specification discloses honeybee repellents exhibiting repellent properties similar to 2-heptanone, compositions comprising such repellents, uses to repel a honeybee from a mammal, location, plant, structure treated of such repellents, and methods of treating a mammal, location, plant, structure by applying such repellents.. .
Inscent, Inc.

Method of determining disease causality of genome mutations

A method of identifying a gene or genomic mutation that is linked to causality of a neuropsychiatric disorder is provided. The method comprises identifying exons which exhibit an expression level that is at least within the 75th percentile of exon expression levels within a nucleic acid-containing sample from a mammal having a neuropsychiatric disorder; comparing the sequence of each identified exon to the sequence of a corresponding exon from a healthy control to identify rare or de novo sequence mutations within the identified exon; calculating the burden of rare or de novo mutations within the exon; and determining the correlation between expression level of the identified exon and burden of de novo or rare mutations in the exon, wherein an inverse correlation indicates that the exon gene is linked to causality of the neuropsychiatric disorder..
The Hospital For Sick Children

Improved recombinant polypeptide production methods

Herein is reported a method for producing a fusion-polypeptide comprising the steps of a) cultivating a mammalian cell comprising a nucleic acid encoding a variant fusion-polypeptide wherein the amino acid sequence of the fusion-polypeptide has been modified by replacing in a pro-fusion-polypeptide the endogenous protease cleavage site between the pro-peptide and the fusion-polypeptide with an exogenous (with respect to the origins of the parts of the fusion-polypeptide) or artificial protease cleavage site, and b) recovering the fusion-polypeptide or fusion-pro-polypeptide from the cell or the cultivation medium and thereby producing the (recombinant) fusion-polypeptide.. .
Hoffmann-la Roche Inc.

Transgenic production of heparin

The disclosure provides methods, cells and transgenic non human mammals for the production of heparin. Specifically, the method comprising providing a transgenic non human mammal or mammary epithelial cells modified to express one or more heparin biosynthesis enzymes, and harvesting heparin produced.
Lfb Usa, Inc.

Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine

And pharmaceutically acceptable acid addition salts thereof, which is useful for prophylaxis and treatment of respiratory syncytial virus (rsv) infection in mammal or human being.. .

Compositions and methods for treatment of exercise-induced pulmonary hemorrhage or nasopharyngeal cicatrix

Methods, compositions, and medical device systems relating to treating exercise-induced pulmonary hemorrhage (eiph) and nasopharyngeal cicatrix (nc) in a mammal. For example, one method comprises administering through inhalation a composition comprising a physiologically acceptable carrier and one or more stem cell derived factors, such as stem cell factors secreted by cultured mesenchymal stem cells (mscs).
Riddle Institute

Treatment of eye disease

A method of treating an eye disease comprising administering an adeno-associated virus (aav) vector to a mammalian subject by subretinal injection, wherein the aav vector comprises a nucleotide sequence encoding melanopsin operably linked to an expression control sequence to promote expression of melanopsin in cells of the eye of the subject.. .
Isis Innovation Limited

Casein peptide for use in the treatment of uterine infections

The present disclosure relates to a casein peptide for use in the treatment of an uterine infection in a female mammalian animal, to methods of treatment of such infections by administering to a female mammalian animal at least one casein peptide, to the use of casein peptide for the preparation of a pharmaceutical composition for treatment of uterine infection and to a kit for said treatment. The casein peptide is preferably a casein hydrolysate, e.g.
Mileutis Ltd.

Pomegranate skin extract for treating fatty liver

Use of a pomegranate skin extract for use in the treatment of metabolic syndrome, more particularly, fatty liver disease. More particularly, the pomegranate skin extract is used in inhibiting body weight gain in the prevention and/or the treatment of fatty liver disease in mammals..
Nestec S.a.

Multipotent and immunocompatible stem cell concentrate

The present invention generally relates to a stem cell concentrate isolated from a mammalian vascularized adipose tissue, biopharmaceuticals containing such concentrate and use thereof in therapies for treating diseases in mammals.. .
Regenera - Medicina VeterinÁria AvanÇada Ltda.

Nanoclustered water having improved medical utility

The present invention relates to methods of treating or preventing an infection or infectious disease in a mammal, or sanitizing mammalian tissue, or treating or preventing psoriasis in a mammal, comprising topically administering to said mammal an electrolytic acid water comprising free chlorine, wherein: a) from 90% to 99.9% of said free chlorine is present in the form of hypochlorous acid; b) said water has a ph of from 0.5 to 5.0; and c) said water has oxidation reduction potential (orp) of greater than 1100 mv. The present invention also relates to methods of healing, repair or regeneration of a tissue in a mammal comprising topically administering to said tissue said electrolytic acid water..
Apr Nanotechnologies S.a.

Controlled release fatty acid compositions for use in body reconstruction and body-shaping

The present invention is directed to compositions comprising physiologically acceptable, metabolic lipids, and physiologically acceptable, preferably biodegradable controlled release (cr) compounds, wherein the lipids are cell-free and the cr compounds release the metabolic lipids over a delayed time period under physiological conditions. In addition, the present invention relates to the use of such a composition for producing a cosmetic or therapeutic composition, preferably for fat tissue expansion or fat tissue repair.
Pb&b Sa

Compositions and their use to treat complications of aneurysmal subarachnoid hemmorrhage

The described invention provides a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury using a flowable sustained release particulate composition.. .
Edge Therapeutics, Inc.

Oral rapamycin nanoparticle preparations and use

Oral preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The preparations are intended to assist with the treatment and prevention of cancer, neurocognitive dysfunction, genetically predisposed disorders, and age-related disorders.
Rapamycin Holdings, Inc.

Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells

A method of preferentially delivering an active agent to an immune cell, such as a myeloid progenitor cell, a dendritic cell, a monocyte, a macrophage or a t-lymphocyte, or other cell type restricted to a functional organ system or an anatomic entity, of a mammalian subject by administering a lipid-drug complex to the subject. The lipid-drug complex is comprised of an active agent, such as a drug, and an outer surface with a targeting ligand that binds a marker on the surface of the immune cell or other cell type that is infected with or susceptible to infection with an infectious agent.
Rodos Biotarget Gmbh

Intrathecal administration, preferably intraventricular, of mtor inhibitors for the therapy of some neurodegenerative, neuroinflammatory and neuro-oncologic diseases

The invention relates to the use of inhibitors of the enzyme mtor kinase (mammalian target of rapamycin) in the treatment of neuro-oncologic diseases, in particular tuberous sclerosis, neurodegenerative diseases, in particular alzheimer's disease, and neuroinflammatory diseases, in particular multiple sclerosis and primary progressive aphasia, via intrathecal, or preferably intraventricular, administration of said inhibitors.. .

Compositions for application to the skin for reducing adhesion of pollution particles on skin and methods of preparing same

Provided in various embodiments are compositions for topical application to the skin of a mammal, methods for their preparation, and their uses in skin care compositions to reduce adhesion of unwanted particles to the skin. When a hydrophobic non-volatile solvent and a hydrophobic non-volatile high melting point material with a melting point in the range of 60° c.
Dow Corning Europe S.a.

Methods for the noninvasive determination of perfusion, blood flow, and capillarity

A framework for the accurate and noninvasive determination of perfusion in a mammal is provided, including a novel scaling law of a form-function relationship between the number of capillaries in a vascular network as compared to the perfusion of such network. Methods are disclosed that apply such scaling laws in connection with the steps of determining a capillary density of a targeted tissue comprising at least a portion of a capillary network, and calculating perfusion of the targeted tissue based on the determined capillary density of the targeted tissue.

Method of feeding young monogastric mammals and compositions fed to young monogastric mammals

A method of feeding a monogastric mammal, the method including feeding the monogastric mammal a milk replacer during a feeding period and feeding the monogastric mammal a psyllium composition during the feeding period.. .
Purina Animal Nutrition Llc

Method for screening for diet providing production of milk having immunoregulatory action

A diet or a substance providing production of breast milk having an immunoregulatory action is screened for by identifying a diet or a substance that increases or decreases amount of mrna present in milk of a mammal using correlation of mrna profile in the milk and a diet ingested by the mammal or a substance contained in the diet as an index.. .
Morinaga Milk Industry Co., Ltd.

Preservation of the biological activity of undenatured type ii collagen

The instant invention is the storage of type ii collagen containing tissue in carbonated water. Such type ii collagen is useful for alleviating the symptoms of arthritis in mammals as well as the treatment of arthritis in mammals.

Transgenic transchromosomal rodents for making human antibodies

The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.. .
E.r. Squibb & Sons, L.l.c.

Organ regeneration method utilizing ips cell and blastocyst complementation

It is revealed that an organ such as pancreas can be regenerated by utilizing a fact that the deficiency of an organ is complemented by injecting an induced pluripotent stem cell (ips cell) into a developed blastocyst in a blastocyst complementation method. Thus, the present invention has solved the above-described object.
The University Of Tokyo

Assay for detection of transient intracellular ca2+

This invention relates to a simple end point assay for detection of transient intracellular ca2+ with broad applicability to many ca2+ channel proteins comprising, generation of expression constructs for the fusion proteins having the ca2+/calmodulin dependent protein kinase ii (camkii) phosphorylation sites of nr2a or nr2b subunits of n-methyl-d-aspartate receptor (nmdar) or the voltage gated potassium channel of drosophila (eag) or any protein sequence which binds to the t-site of camkii similar to nr2b, conjugated to mitochondrial localizing signal sequence, or mutants of these sequences as described herein. Generation of mammalian expression constructs of α-camk11 as a chimera with green fluorescent protein (gfp-α-camkii) or its mutants as described herein.
Department Of Biotechnology

Multiplex guide rnas

Methods and constructs for the multiplex expression of highly active crispr guide rnas (grnas) from rna polymerase ii and iii promoters, optionally in mammalian cells. The present invention is based, at least in part, on the discovery that csy4, an endoribonuclease that recognizes a short rna hairpin sequence, can be used to cleave out multiple functional grnas encoded on a single longer rna transcript (produced from an rna pol ii or iii promoter) in which the individual grnas are separated by csy4 cleavage sites..
The General Hospital Corporation

Gene editing in the oocyte by cas9 nucleases

The present invention relates to a method of producing a non-human, mammalian oocyte carrying a modified target sequence in its genome, the method comprising the steps of introducing into a non-human, mammalian oocyte: (a) a clustered, regularly interspaced, short palindromic repeats (crispr)-associated protein 9 (cas9 protein) or a nucleic acid molecule encoding said cas9 protein; and (b-i) a target sequence specific crispr rna (crrna) and a trans-activating crrna (tracr rna) or a nucleic acid molecule encoding said rnas; or (b-ii) a chimaeric rna sequence comprising a target sequence specific crrna and tracrrna or a nucleic acid molecule encoding said rna; wherein the cas9 protein introduced in (a) and the rna sequence(s) introduced in (b-i) or (b-ii) form a protein/rna complex that specifically binds to the target sequence and introduces a single or double strand break within the target sequence. The present invention further relates to the method of the invention, wherein the target sequence is modified by homologous recombination with a donor nucleic acid sequence further comprising the step: (c) introducing a nucleic acid molecule into the cell, wherein the nucleic acid molecule comprises the donor nucleic acid sequence and regions homologous to the target sequence.
Helmholtz Zentrum MÜnchen Deutsches Forschungszentrum FÜr Gesundheit Und Umwelt

Vaccine targeting il-17a

The present invention provides a vaccine against il-17a, which uses, as an immunogen, a polypeptide containing the amino acid sequence shown in seq id no: 1, or an amino acid sequence derived from a non-human mammal, which corresponds to seq id no: 1, a prophylactic or therapeutic agent containing the vaccine for diseases involving il-17a as an aggravation factor, and the like.. .
Osaka University

Substituted aminopyrimidine compounds and methods of use

The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the pi3k enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which pi3k enzymes play a role in leukocyte function, and hyperproliferative disorders associated with pi3k activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans..
Sunshine Lake Pharma Co., Ltd.

Substituted aminopyrimidine compounds and methods of use

The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the pi3k enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which pi3k enzymes play a role in leukocyte function, and hyperproliferative disorders associated with pi3k activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans..
Calitor Sciences, Llc

Surgical device with integrated visualization and cauterization

Surgical devices with integrated, visualization and cauterization are described herein where such devices include an elongate structure having a central lumen and an expandable space-creating structure having at least one expandable leaflet mounted in the vicinity of the distal end and is configured for placement within a mammalian body proximate to a therapeutic target. Also included is a proximal terminal having an actuator mounted in the vicinity of the proximal end and is configured to remain outside of said body and provide an actuation mechanism for actuating the space-creating structure.
Aminex, Inc.

Plasmapheresis device

A plasmapheresis device includes a column or other flow mechanism in which plasma flows following separation of the plasma from cellular components like blood cells, platelets and the like. The column includes a moiety, such as an antibody, which selectively binds to galectin-3.
Eliaz Therapeutics, Inc.

Endoscopic mucosal resectioning using purified inverse thermosensitive polymers

One aspect of the invention relates to use of a composition comprising a purified inverse thermosensitive polymer in an endoscopic procedure for gastrointestinal mucosal resectioning in a mammal. Another aspect of the invention relates to a method of 5gastrointestinal mucosal resectioning, comprising administering submucosally to a region of a gastrointestinal mucosa in a mammal an effective amount of a composition comprising a purified inverse thermosensitive polymer; and surgically resecting said region of gastrointestinal mucosa.
Genzyme Corporation

Solid dressing for treating wounded tissue

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings..
Stb, Ltd.

Non-human mammal model of human degenerative disorder, uses thereof, and treating human degenerative disorder

The present application relates to a non-human mammal model of a human neurodegenerative disorder, methods of producing the non-human mammal model, and methods of using the non-human mammal model to identify agents suitable for treating a neurodegenerative disorder. The present application also relates to methods of treating neurodegenerative disorders and restoring normal brain interstitial potassium levels..
University Of Rochester

Drug delivery devices and growth factor formulations for accelerated wound healing

The present invention is directed to novel drug delivery devices and pharmaceutical compositions containing growth and differentiation factor proteins. Said devices and compositions are specifically designed to accelerate tissue regeneration and wound healing processes of mammalian tissues.
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh

Bacterial compositions and methods of use thereof for treatment of immune system disorders

Provided are compositions containing combinations of bacteria useful for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract, or other niche of a mammalian subject, and methods for use thereof, in particular for the treatment, inhibition, or prevention of immune disorders such as allergies and asthma.. .
Seres Therapeutics, Inc.

Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)

The present invention relates to an active (immunostimulatory) composition comprising at least one rna, preferably a mrna, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (nsclc), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto.
Curevac Ag

Novel compositions and uses thereof

The present invention provides a composition for stimulating hair growth in a mammal comprising a modified osteopontin polypeptide in which an rgd domain is inactivated; and a pharmaceutically acceptable and/or cosmetically acceptable excipient, carrier or diluent. The invention further provides methods of stimulating hair growth in a mammal..
Folicum Ab

Methods and compositions for preventing or treating dominant optic atrophy

The disclosure generally describes methods of preventing or treating dominant optic atrophy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
Stealth Bio Therapeutics Corp

Methods for reducing oxidative damage

The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide.
Cornell Research Foundation, Inc.

Adipose tissue mesenchymal stem cells and methods of use to treat or inhibit uterine disorders

There is a high stem cell therapy potential in the field of reproductive disorders. Endometriosis is a common finding in women with infertility.
Avita International Ltd.

Antihistamines in combination with a range of substances for improved health

The present invention provides for novel combinations comprising an antihistamine with selected pharmaceutical and nutraceutical agents which alleviate some of the symptoms experienced by menopausal women, optionally combined further with a range of indole-based natural products such as l-tryptophan, 5-hydroxytryptophan and melatonin. These mixtures may be enriched further with pharmaceutically acceptable calcium and magnesium salts as well as selected b vitamins.
Requis Pharmaceuticals, Inc.

Reducing memory loss in mammals suffering from alzheimer's disease

The disclosure relates to methods and compositions for reducing memory loss. Specifically, methods of using inhibitors of gat-3 polypeptide activity to reduce memory loss in mammals suffering from alzheimer's disease (ad) are provided.
The Penn State Research Foundation

Use of ep4 receptor antagonists in the treatment of cartilage disease

This invention relates to a compound with ep4 antagonistic activity, or a pharmaceutically acceptable salt with ep4 receptor antagonistic activities, which is useful in the treatment of cartilage disease. This invention also relates to a compound of formula (i), (ii), (iii), (iv), (va) or (vb), or a pharmaceutically acceptable salt thereof with ep4 receptor antagonistic activities, which is useful in the treatment of cartilage disease.
Askat Inc.

Benzamides and related inhibitors of factor xa

Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor xa are described. Compositions containing such compounds are also described.
Millennium Pharmaceuticals, Inc.

Solid dressing for treating wounded tissue

Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of fibrinogen and a fibrinogen activator, wherein the fibrinogen is present in an amount between 3.0 mg/cm2 of the wound facing surface of the dressing and 13.0 mg/cm2 of the wound facing surface of the dressing. Also disclosed are methods for treating wounded tissue..
Stb, Ltd.





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Mammal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mammal with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.3427

file did exist - 2769

2 - 1 - 66